{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T17:54:00Z","timestamp":1722794040747},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00213-014-3507-4","type":"journal-article","created":{"date-parts":[[2014,2,27]],"date-time":"2014-02-27T08:27:10Z","timestamp":1393489630000},"page":"3729-3744","source":"Crossref","is-referenced-by-count":6,"title":["Behavioural profile of exendin-4\/naltrexone dose combinations in male rats during tests of palatable food consumption"],"prefix":"10.1007","volume":"231","author":[{"given":"F. L.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"key":"3507_CR1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brainres.2005.03.011","volume":"1044","author":"CR Abbott","year":"2005","unstructured":"Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR et al (2005) The inhibitory effects of peripheral administration of peptide YY (30-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal brainstem-hypothalamic pathway. Brain Res 1044:127\u2013131","journal-title":"Brain Res"},{"key":"3507_CR2","first-page":"133","volume":"36","author":"RAH Adan","year":"2013","unstructured":"Adan RAH (2013) Mechanisms underlying current and future anti-obesity drugs. TINS 36:133\u2013140","journal-title":"TINS"},{"key":"3507_CR3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jn\/132.5.990","volume":"132","author":"A Aziz","year":"2002","unstructured":"Aziz A, Anderson GH (2002) Exendin-4, a GLP-1 receptor agonist, modulates the effect of macronutrients on food intake by rats. J Nutr 132:990\u2013995","journal-title":"J Nutr"},{"key":"3507_CR4","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/jn\/133.7.2326","volume":"133","author":"A Aziz","year":"2003","unstructured":"Aziz A, Anderson GH (2003) Exendin-4, a GLP-1 receptor agonist, interacts with proteins and their products of digestion to suppress food intake in rats. J Nutr 133:2326\u20132330","journal-title":"J Nutr"},{"key":"3507_CR5","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131\u20132157","journal-title":"Gastroenterology"},{"key":"3507_CR6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrendo.2011.77","volume":"7","author":"JG Barrera","year":"2011","unstructured":"Barrera JG, Sandoval DA, D\u2019Alessio DA, Seeley RJ (2011) GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Revs Endocrinol 7:507\u2013516","journal-title":"Nat Revs Endocrinol"},{"key":"3507_CR7","doi-asserted-by":"crossref","first-page":"R945","DOI":"10.1152\/ajpregu.00275.2010","volume":"299","author":"NT Bello","year":"2010","unstructured":"Bello NT, Kemm MH, Ofeldt EM, Moran TH (2010) Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Regul Integr Comp Physiol 299:R945\u2013R952","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3507_CR8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.physbeh.2009.02.044","volume":"97","author":"KC Berridge","year":"2009","unstructured":"Berridge KC (2009) \u2018Liking\u2019 and \u2018wanting\u2019 food rewards: brain substrates and roles in eating disorders. Physiol Behav 97:537\u2013550","journal-title":"Physiol Behav"},{"key":"3507_CR9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.peptides.2004.01.006","volume":"25","author":"RJ Bodnar","year":"2004","unstructured":"Bodnar RJ (2004) Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides 25:697\u2013725","journal-title":"Peptides"},{"key":"3507_CR10","first-page":"349","volume":"58","author":"E Bojanowska","year":"2007","unstructured":"Bojanowska E, Nowak A (2007) Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. J Physiol Pharmacol 58:349\u2013360","journal-title":"J Physiol Pharmacol"},{"key":"3507_CR11","first-page":"395","volume":"62","author":"E Bojanowska","year":"2011","unstructured":"Bojanowska E, Radziszewska E (2011) Combined stimulation of glucagon-like peptide-1 receptor agonist and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat. J Physiol Pharmacol 62:395\u2013402","journal-title":"J Physiol Pharmacol"},{"key":"3507_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2141\/jpsa.36.109","volume":"26","author":"T Bungo","year":"1999","unstructured":"Bungo T, Shimojo M, Masuda Y, Saito N, Sugahara K, Hasegawa et al (1999) Effect of naloxone on the anorexic action by glucagon-like peptide-1 (7-36) in the neonatal chick. Jap Poult Sci 26:109\u2013115","journal-title":"Jap Poult Sci"},{"key":"3507_CR13","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","volume":"27","author":"JB Buse","year":"2004","unstructured":"Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (2004) Effects of exenatide (exendin-4) on glycemic control over 30\u00a0weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628\u20132635","journal-title":"Diabetes Care"},{"key":"3507_CR14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","volume":"154","author":"JB Buse","year":"2011","unstructured":"Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AYM et al (2011) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomised controlled trial. Ann Intern Med 154:103\u2013112","journal-title":"Ann Intern Med"},{"key":"3507_CR15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2013.01.013","volume":"70","author":"SW Chan","year":"2013","unstructured":"Chan SW, Lin G, Yew DTW, Yeung CK, Rudd JA (2013) Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist, in Suncus murinus (house musk shrew). Neuropharmacology 70:141\u2013147","journal-title":"Neuropharmacology"},{"key":"3507_CR16","doi-asserted-by":"crossref","first-page":"R1695","DOI":"10.1152\/ajpregu.00870.2004","volume":"288","author":"PK Chelikani","year":"2005","unstructured":"Chelikani PK, Haver AC, Reidelberger RD (2005) Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 288:R1695\u2013R1706","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3507_CR17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0091-3057(89)90422-X","volume":"33","author":"SJ Cooper","year":"1989","unstructured":"Cooper SJ, Turkish S (1989) Effects of naltrexone on food preference and concurrent behavioral responses in food deprived rats. Pharmacol Biochem Behav 33:17\u201320","journal-title":"Pharmacol Biochem Behav"},{"key":"3507_CR18","first-page":"143","volume-title":"Endorphins, opiates and behavioural processes","author":"SJ Cooper","year":"1988","unstructured":"Cooper SJ, Jackson A, Kirkham TC, Turkish S (1988) Endorphins, opiates and food intake. In: Rodgers RJ, Cooper SJ (eds) Endorphins, opiates and behavioural processes. Wiley, Chichester, pp 143\u2013186"},{"key":"3507_CR19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","volume":"5","author":"JW Day","year":"2009","unstructured":"Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749\u2013757","journal-title":"Nat Chem Biol"},{"key":"3507_CR20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"RA DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30\u00a0weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092\u20131100","journal-title":"Diabetes Care"},{"key":"3507_CR21","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","volume":"32","author":"SL Dickson","year":"2012","unstructured":"Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32:4812\u20134820","journal-title":"J Neurosci"},{"key":"3507_CR22","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1523\/JNEUROSCI.3262-11.2011","volume":"31","author":"AM Dossat","year":"2011","unstructured":"Dossat AM, Lilly N, Kay K, Williams DL (2011) Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci 31:14453\u201314457","journal-title":"J Neurosci"},{"key":"3507_CR23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696\u20131705","journal-title":"Lancet"},{"key":"3507_CR24","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","volume":"291","author":"CM Edwards","year":"2001","unstructured":"Edwards CM, Stanley SA, Davis R, Byrnes AE, Frost GS, Seal LJ et al (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 291:E155\u2013E161","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3507_CR25","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","volume":"106","author":"K Erreger","year":"2012","unstructured":"Erreger K, Davis AR, Poe A, Greig NH, Stanwood GD, Galli A (2012) Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav 106:574\u2013578","journal-title":"Physiol Behav"},{"key":"3507_CR26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","volume":"101","author":"A Flint","year":"1998","unstructured":"Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515\u2013520","journal-title":"J Clin Invest"},{"key":"3507_CR27","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","volume":"7","author":"R Goke","year":"1995","unstructured":"Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP (1995) Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7:2294\u20132300","journal-title":"Eur J Neurosci"},{"key":"3507_CR28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K et al (2009) Rational design of a combination medication for the treatment of obesity. Obesity 17:30\u201339","journal-title":"Obesity"},{"key":"3507_CR29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0091-3057(98)00032-X","volume":"61","author":"JCG Halford","year":"1998","unstructured":"Halford JCG, Wanninayake SCD, Blundell JE (1998) Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159\u2013168","journal-title":"Pharmacol Biochem Behav"},{"key":"3507_CR30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrendo.2010.19","volume":"6","author":"JCG Halford","year":"2010","unstructured":"Halford JCG, Boyland EJ, Blundell JE et al (2010) Pharmacological management of appetite expression in obesity. Nat Revs Endocrinol 6:255\u2013269","journal-title":"Nat Revs Endocrinol"},{"key":"3507_CR31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2012.01.007","volume":"63","author":"JA Harrold","year":"2012","unstructured":"Harrold JA, Dovey TM, Blundell JE, Halford JCG (2012) CNS regulation of appetite. Neuropharmacology 63:3\u201317","journal-title":"Neuropharmacology"},{"key":"3507_CR32","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/oby.2011.50","volume":"19","author":"MR Hayes","year":"2011","unstructured":"Hayes MR, Kanowski SE, Alhadeff AL, Grill HJ (2011) Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity 19:1342\u20131349","journal-title":"Obesity"},{"key":"3507_CR33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neuropharm.2012.01.017","volume":"63","author":"DJ Heal","year":"2012","unstructured":"Heal DJ, Gosden J, Smith SL (2012) What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 63:132\u2013146","journal-title":"Neuropharmacology"},{"key":"3507_CR34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","volume":"143","author":"RJ Heine","year":"2005","unstructured":"Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomised trial. Ann Intern Med 143:559\u2013569","journal-title":"Ann Intern Med"},{"key":"3507_CR35","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409\u20131439","journal-title":"Physiol Rev"},{"key":"3507_CR36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0031-9384(03)00066-0","volume":"79","author":"Y Ishii","year":"2003","unstructured":"Ishii Y, Blundell JE, Halford JCG, Rodgers RJ (2003) Effects of systematic variation in presatiation and fasting on the behavioural satiety sequence in male rats. Physiol Behav 79:227\u2013238","journal-title":"Physiol Behav"},{"key":"3507_CR37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.physbeh.2004.01.009","volume":"81","author":"Y Ishii","year":"2004","unstructured":"Ishii Y, Blundell JE, Halford JCG, Upton N, Porter R, Johns A et al (2004) Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol Behav 81:129\u2013140","journal-title":"Physiol Behav"},{"key":"3507_CR38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbr.2004.11.011","volume":"160","author":"Y Ishii","year":"2005","unstructured":"Ishii Y, Blundell JE, Halford JCG, Upton N, Porter R, Johns A et al (2005) Satiety enhancement by selective orexin-1 receptor antagonist SB-334867: influence of test context and profile comparison with CCK-8S. Behav Brain Res 160:11\u201324","journal-title":"Behav Brain Res"},{"key":"3507_CR39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1345\/aph.1E245","volume":"39","author":"SV Joy","year":"2005","unstructured":"Joy SV, Rodgers PT, Scates AC (2005) Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother 39:110\u2013118","journal-title":"Ann Pharmacother"},{"key":"3507_CR40","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/en.2011-0174","volume":"152","author":"SE Kanoski","year":"2011","unstructured":"Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR (2011) Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally-administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152:3103\u20133112","journal-title":"Endocrinology"},{"key":"3507_CR41","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","volume":"62","author":"SE Kanoski","year":"2012","unstructured":"Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR (2012) The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 62:1916\u20131927","journal-title":"Neuropharmacology"},{"key":"3507_CR42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","volume":"28","author":"DM Kendall","year":"2005","unstructured":"Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al (2005) Effects of exenatide (exendin-4) on glycemic control over 30\u00a0weeks in patients with type 2 diabetes treated with metformin and sulfonylurea. Diabetes Care 28:1083\u20131091","journal-title":"Diabetes Care"},{"key":"3507_CR43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pbb.2010.07.020","volume":"97","author":"GA Kennett","year":"2010","unstructured":"Kennett GA, Clifton PG (2010) New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 97:63\u201383","journal-title":"Pharmacol Biochem Behav"},{"key":"3507_CR44","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","volume":"136","author":"TJ Kieffer","year":"1995","unstructured":"Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585\u20133596","journal-title":"Endocrinology"},{"key":"3507_CR45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0195-6663(84)80049-5","volume":"5","author":"TC Kirkham","year":"1984","unstructured":"Kirkham TC, Blundell JE (1984) Dual action of naloxone on feeding revealed by behavioural analysis: separate effects on initiation and termination of eating. Appetite 5:45\u201352","journal-title":"Appetite"},{"key":"3507_CR46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0091-3057(86)90241-8","volume":"25","author":"TC Kirkham","year":"1986","unstructured":"Kirkham TC, Blundell JE (1986) Effect of naloxone and naltrexone on the development of satiation measured in the runway: comparisons with d-amphetamine and d-fenfluramine. Pharmacol Biochem Behav 25:123\u2013128","journal-title":"Pharmacol Biochem Behav"},{"key":"3507_CR47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0091-3057(87)90158-4","volume":"26","author":"TC Kirkham","year":"1987","unstructured":"Kirkham TC, Blundell JE (1987) Effects of naloxone and naltrexone on meal patterns of freely-feeding rats. Pharmacol Biochem Behav 26:515\u2013520","journal-title":"Pharmacol Biochem Behav"},{"key":"3507_CR48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130000596","volume":"153","author":"TC Kirkham","year":"2001","unstructured":"Kirkham TC, Williams CM (2001) Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 153:267\u2013270","journal-title":"Psychopharmacology"},{"key":"3507_CR49","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"2","author":"B Kreymann","year":"1987","unstructured":"Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300\u20131304","journal-title":"Lancet"},{"key":"3507_CR50","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1210\/endo.138.10.5270","volume":"138","author":"PJ Larsen","year":"1997","unstructured":"Larsen PJ, Tang-Christensen M, Jessop DS (1997) Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445\u20134455","journal-title":"Endocrinology"},{"key":"3507_CR51","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.2337\/diabetes.50.11.2530","volume":"50","author":"PJ Larsen","year":"2001","unstructured":"Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M (2001) Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530\u20132539","journal-title":"Diabetes"},{"key":"3507_CR52","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ijo.2012.16","volume":"37","author":"N-C Liang","year":"2013","unstructured":"Liang N-C, Bello NT, Moran TH (2013) Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations. Int J Obes 37:272\u2013278","journal-title":"Int J Obes"},{"key":"3507_CR53","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.ijo.0803284","volume":"30","author":"CM Mack","year":"2006","unstructured":"Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA et al (2006) Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes 30:1332\u20131340","journal-title":"Int J Obes"},{"key":"3507_CR54","doi-asserted-by":"crossref","first-page":"R1755","DOI":"10.1152\/ajpregu.00472.2011","volume":"301","author":"NJ McKay","year":"2011","unstructured":"McKay NJ, Kanoski SE, Hayes MR, Daniels D (2011) Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake. Am J Physiol Regul Integr Comp Physiol 301:R1755\u2013R1764","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3507_CR55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1210\/endo.140.1.6421","volume":"140","author":"K Meeran","year":"1999","unstructured":"Meeran K, O\u2019Shea D, Edwards CM, Turton MD, Heath MM, Gunn I et al (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1 (7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244\u2013250","journal-title":"Endocrinology"},{"key":"3507_CR56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","volume":"214","author":"R Mentlein","year":"1993","unstructured":"Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine, and is responsible for their degradation in human serum. Eur J Biochem 214:829\u2013835","journal-title":"Eur J Biochem"},{"key":"3507_CR57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","volume":"403","author":"I Merchenthaler","year":"1999","unstructured":"Merchenthaler I, Lane M, Shughrue P (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261\u2013280","journal-title":"J Comp Neurol"},{"key":"3507_CR58","doi-asserted-by":"crossref","first-page":"5250530","DOI":"10.1093\/ajcn\/68.3.525","volume":"68","author":"E Naslund","year":"1998","unstructured":"Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM (1998) Glucagon-like peptide-1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68:5250530","journal-title":"Am J Clin Nutr"},{"key":"3507_CR59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.ijo.0800818","volume":"23","author":"E Naslund","year":"1999","unstructured":"Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ et al (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304\u2013311","journal-title":"Int J Obes Relat Metab Disord"},{"key":"3507_CR60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","volume":"117","author":"LL Nielsen","year":"2004","unstructured":"Nielsen LL, Young AA, Parkes DG (2004) Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control in type 2 diabetes. Reg Pept 117:77\u201388","journal-title":"Reg Pept"},{"key":"3507_CR61","first-page":"1117","volume":"10","author":"R Padwal","year":"2009","unstructured":"Padwal R (2009) Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs 10:1117\u20131125","journal-title":"Curr Opin Investig Drugs"},{"key":"3507_CR62","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.neuroimage.2008.09.047","volume":"44","author":"JRC Parkinson","year":"2009","unstructured":"Parkinson JRC, Chaudri OB, Kuo Y-T, Field BCT, Herily AH, Dhillo WS et al (2009) Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). NeuroImage 44:1022\u20131031","journal-title":"NeuroImage"},{"issue":"224-OR","key":"3507_CR63","first-page":"A61","volume":"60","author":"M Paulik","year":"2011","unstructured":"Paulik M, Hamilton B, Hommel J, Holt L, Herring C, Stroup A et al (2011) Combined long-acting PYY and GLP-1 agonism synergistically normalizes weight and glucose in obese and diabetic mice. Diabetes 60(224-OR):A61","journal-title":"Diabetes"},{"key":"3507_CR64","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2337\/db05-0996","volume":"56","author":"D Perez-Tilve","year":"2007","unstructured":"Perez-Tilve D, Gonzalez-Matias L, Alvarez-Crespo M, Leiras R, Tovar S, Dieguez C, Mallo F (2007) Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 56:143\u2013151","journal-title":"Diabetes"},{"key":"3507_CR65","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjmed.2009.12.007","volume":"123","author":"A Peters","year":"2010","unstructured":"Peters A (2010) Incretin-based therapies: a review of current clinical trial data. Am J Med 123:S28\u2013S37","journal-title":"Am J Med"},{"key":"3507_CR66","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0014-2999(02)01551-0","volume":"442","author":"TA Pietras","year":"2002","unstructured":"Pietras TA, Rowland NE (2002) Effect of opioid and cannabinoid receptor antagonism on orphanin FQ-induced hyperphagia in rats. Eur J Pharmacol 442:237\u2013239","journal-title":"Eur J Pharmacol"},{"key":"3507_CR67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0091270010367653","volume":"51","author":"NR Pinelli","year":"2011","unstructured":"Pinelli NR, Jantz A, Smith Z, Abouhassan A, Ayar C, Jaber NA et al (2011) Effect of administration of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers. J Clin Pharmacol 51:165\u2013172","journal-title":"J Clin Pharmacol"},{"key":"3507_CR68","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/oby.2011.342","volume":"20","author":"CE Pritchett","year":"2012","unstructured":"Pritchett CE, Hajnal A (2012) Glucagon-like peptide-1 regulation of carbohydrate intake is differentially affected by obesogenic diets. Obesity 20:313\u2013317","journal-title":"Obesity"},{"key":"3507_CR69","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","volume":"8","author":"RE Ratner","year":"2006","unstructured":"Ratner RE, Maggs D, Nielsen LL, Styonehouse AH, Poon T, Zhang B et al (2006) Long-term effects of exenatide therapy over 82\u00a0weeks on glycemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 8:419\u2013428","journal-title":"Diabetes Obes Metab"},{"key":"3507_CR70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/oby.2010.136","volume":"19","author":"RD Reidelberger","year":"2011","unstructured":"Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM (2011) Effects of exendin-4 alone and with peptide YY (3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 19:121\u2013127","journal-title":"Obesity (Silver Spring)"},{"key":"3507_CR71","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/dmrr.646","volume":"22","author":"MC Riddle","year":"2006","unstructured":"Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH et al (2006) Exenatide elicits sustained glycemic control and progressive reduction in body weight in patients with type 2 diabetes inadequately controlled by sulfonylureas with or without metformin. Diabetes Metab Res Rev 22:483\u2013491","journal-title":"Diabetes Metab Res Rev"},{"key":"3507_CR72","doi-asserted-by":"crossref","first-page":"R582","DOI":"10.1152\/ajpregu.1999.277.2.R582","volume":"277","author":"L Rinaman","year":"1999","unstructured":"Rinaman L (1999a) Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol Regul Integr Comp Physiol 277:R582\u2013R590","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3507_CR73","doi-asserted-by":"crossref","first-page":"R1537","DOI":"10.1152\/ajpregu.1999.277.5.R1537","volume":"277","author":"L Rinaman","year":"1999","unstructured":"Rinaman L (1999b) A functional role for central glucagon-like peptide-1 receptors in lithium-induced anorexia. Am J Physiol Regul Integr Comp Physiol 277:R1537\u20131540","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3507_CR74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.brainres.2010.03.059","volume":"1350","author":"L Rinaman","year":"2010","unstructured":"Rinaman L (2010) Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Res 1350:18\u201334","journal-title":"Brain Res"},{"key":"3507_CR75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pbb.2010.03.001","volume":"97","author":"RJ Rodgers","year":"2010","unstructured":"Rodgers RJ, Holch P, Tallett AJ (2010) Behavioural satiety sequence (BSS): separating wheat from chaff in the behavioural pharmacology of appetite. Pharmacol Biochem Behav 97:3\u201314","journal-title":"Pharmacol Biochem Behav"},{"key":"3507_CR76","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dmm.009621","volume":"5","author":"RJ Rodgers","year":"2012","unstructured":"Rodgers RJ, Tsch\u00f6ep MH, Wilding JPH (2012) Anti-obesity drugs: past, present and future. Dis Model Mech 5:621\u2013626","journal-title":"Dis Model Mech"},{"key":"3507_CR77","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/meta.2000.6251","volume":"49","author":"F Rodriguez de Fonseca","year":"2000","unstructured":"Rodriguez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O et al (2000) Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49:709\u2013717","journal-title":"Metabolism"},{"key":"3507_CR78","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2010.01.027","volume":"1350","author":"JD Roth","year":"2010","unstructured":"Roth JD, Trevaskis JL, Turek VF, Parkes DG (2010) \u2018Weighing in\u2019 on synergy: preclinical research on neurohumoral anti-obesity combinations. Brain Res 1350:86\u201394","journal-title":"Brain Res"},{"key":"3507_CR79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-0115(97)01034-3","volume":"71","author":"NE Rowland","year":"1997","unstructured":"Rowland NE, Crews EC, Gentry RM (1997) Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul Pept 71:171\u2013174","journal-title":"Regul Pept"},{"key":"3507_CR80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s002130100910","volume":"159","author":"NE Rowland","year":"2001","unstructured":"Rowland NE, Mukherjee M, Roberston K (2001) Effects of the cannabinoid receptor antagonist SR141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 159:111\u2013116","journal-title":"Psychopharmacology"},{"key":"3507_CR81","doi-asserted-by":"crossref","first-page":"R983","DOI":"10.1152\/ajpregu.00323.2007","volume":"293","author":"KA Scott","year":"2007","unstructured":"Scott KA, Moran TH (2007) The GLP-1 agonist exendin-4 reduces food intake in non-human primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 293:R983\u2013R987","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3507_CR82","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1523\/JNEUROSCI.20-04-01616.2000","volume":"20","author":"RJ Seeley","year":"2000","unstructured":"Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC et al (2000) The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20:1616\u20131621","journal-title":"J Neurosci"},{"key":"3507_CR83","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00125-005-0128-9","volume":"49","author":"L Simonsen","year":"2006","unstructured":"Simonsen L, Holst JJ, Deacon CF (2006) Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomelular filtration in anaesthetised pigs. Diabetologia 49:706\u2013712","journal-title":"Diabetologia"},{"key":"3507_CR84","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/endo.141.6.7490","volume":"141","author":"M Szayna","year":"2000","unstructured":"Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Grieg NH et al (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936\u20131941","journal-title":"Endocrinology"},{"key":"3507_CR85","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.physbeh.2008.02.009","volume":"94","author":"AJ Tallett","year":"2008","unstructured":"Tallett AJ, Blundell JE, Rodgers RJ (2008a) Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. Physiol Behav 94:422\u2013431","journal-title":"Physiol Behav"},{"key":"3507_CR86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.bbr.2007.10.005","volume":"187","author":"AJ Tallett","year":"2008","unstructured":"Tallett AJ, Blundell JE, Rodgers RJ (2008b) Behaviourally-selective hypophagic effects of naloxone in non-deprived male rats presented with palatable food. Behav Brain Res 187:417\u2013427","journal-title":"Behav Brain Res"},{"key":"3507_CR87","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.pbb.2008.08.007","volume":"91","author":"AJ Tallett","year":"2009","unstructured":"Tallett AJ, Blundell JE, Rodgers RJ (2009a) Effects of acute low dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats. Pharmacol Biochem Behav 91:358\u2013366","journal-title":"Pharmacol Biochem Behav"},{"key":"3507_CR88","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.physbeh.2009.01.022","volume":"97","author":"AJ Tallett","year":"2009","unstructured":"Tallett AJ, Blundell JE, Rodgers RJ (2009b) Night and day: diurnal differences in the behavioural satiety sequence in male rats. Physiol Behav 97:125\u2013130","journal-title":"Physiol Behav"},{"key":"3507_CR89","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bbr.2009.10.004","volume":"207","author":"AJ Tallett","year":"2010","unstructured":"Tallett AJ, Blundell JE, Rodgers RJ (2010a) Sibutramine & naloxone: infra-additive interaction in the regulation of appetite? Behav Brain Res 207:174\u2013181","journal-title":"Behav Brain Res"},{"key":"3507_CR90","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pbb.2009.12.010","volume":"97","author":"AJ Tallett","year":"2010","unstructured":"Tallett AJ, Blundell JE, Rodgers RJ (2010b) Effects of low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats. Pharmacol Biochem Behav 97:92\u2013100","journal-title":"Pharmacol Biochem Behav"},{"key":"3507_CR91","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1210\/en.2005-0473","volume":"146","author":"T Talsania","year":"2005","unstructured":"Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL (2005) Peripheral exendin-4 and peptide YY3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 146:3748\u20133756","journal-title":"Endocrinology"},{"key":"3507_CR92","first-page":"R848","volume":"271","author":"M Tang-Christensen","year":"1996","unstructured":"Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M et al (1996) Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848\u2013R856","journal-title":"Am J Physiol"},{"key":"3507_CR93","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0006-8993(98)00584-8","volume":"801","author":"TE Thiele","year":"1998","unstructured":"Thiele TE, Seeley RJ, D-Alessio D, Eng J, Bernstein IL, Woods SC et al (1998) Central infusion of glucagon-like peptide 1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 801:164\u2013170","journal-title":"Brain Res"},{"key":"3507_CR94","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2337\/diab.42.11.1678","volume":"42","author":"B Thorens","year":"1993","unstructured":"Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widman C (1993) Cloning and functional expression of GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-3 (9-39) is an antagonist of the receptor. Diabetes 42:1678\u20131682","journal-title":"Diabetes"},{"key":"3507_CR95","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","volume":"379","author":"MD Turton","year":"1996","unstructured":"Turton MD, O\u2019Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69\u201372","journal-title":"Nature"},{"key":"3507_CR96","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2012.04.001","volume":"63","author":"SP Vickers","year":"2012","unstructured":"Vickers SP, Clifton PG (2012) Animal models to explore the effects of CNS drugs on food intake and energy expenditure. Neuropharmacology 63:124\u2013131","journal-title":"Neuropharmacology"},{"key":"3507_CR97","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1476-5381.2011.01245.x","volume":"164","author":"SP Vickers","year":"2011","unstructured":"Vickers SP, Jackson HC, Cheetham SC (2011) The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol 164:1248\u20131262","journal-title":"Br J Pharmacol"},{"key":"3507_CR98","unstructured":"Weiss SM (1995) Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny owl. PhD Thesis, School of Psychology, University of Leeds (UK)"},{"key":"3507_CR99","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-012-2916-5","volume":"226","author":"FL Wright","year":"2013","unstructured":"Wright FL, Rodgers RJ (2013a) Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology 226:415\u2013431","journal-title":"Psychopharmacology"},{"key":"3507_CR100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-013-3036-6","volume":"228","author":"FL Wright","year":"2013","unstructured":"Wright FL, Rodgers RJ (2013b) Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. Psychopharmacology 228:291\u2013307","journal-title":"Psychopharmacology"},{"key":"3507_CR101","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00213-013-3295-2","volume":"231","author":"FL Wright","year":"2014","unstructured":"Wright FL, Rodgers RJ (2014) On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination. Psychopharmacology 231:787\u2013800","journal-title":"Psychopharmacology"},{"key":"3507_CR102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2012.03.019","volume":"63","author":"AA Young","year":"2012","unstructured":"Young AA (2012) Brainstem sensing of meal-related signals in energy homeostasis. Neuropharmacology 63:31\u201345","journal-title":"Neuropharmacology"},{"key":"3507_CR103","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","volume":"48","author":"AA Young","year":"1999","unstructured":"Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B et al (1999) Glucose-lowering and insulin-sensitising actions of exendin-4. Diabetes 48:1026\u20131034","journal-title":"Diabetes"},{"key":"3507_CR104","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes. Lancet 359:824\u2013830","journal-title":"Lancet"},{"key":"3507_CR105","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/153537020322800810","volume":"228","author":"J Zhou","year":"2003","unstructured":"Zhou J, Roane DS, Xi X, Bogacka I, Li B, Ryan DH et al (2003) Short-term food restriction and refeeding alter expression of genes likely involved in brain glucosensing. Exp Biol Med 228:943\u2013950","journal-title":"Exp Biol Med"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3507-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-014-3507-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3507-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:57:54Z","timestamp":1565225874000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-014-3507-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":105,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["3507"],"URL":"https:\/\/doi.org\/10.1007\/s00213-014-3507-4","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]}}}